Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives

Using the Prosigna-assay for all HR+/HER2- pN0 EBC patients was not cost-effective from a healthcare perspective, but from the societal perspective it was cost-saving. Selecting patients who are clear/uncertain candidates for chemotherapy based on IHC-classification, Prosigna is cost-effective from both perspectives.

Authors

Institutions

Publication Details

Journal
Clinical Breast Cancer
Published
2025-04-15
DOI
https://doi.org/10.1016/j.clbc.2025.04.011
Citations
2
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
1.87
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives

Bjørn Naume, Ragnhild Sørum Falk, Cecilie E. Kiserud, Bård Mannsåker et al.
2 citations
Clinical Breast Cancer
Breast Cancer Treatment Studies
1.87
article

Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives

Bjørn Naume, Ragnhild Sørum Falk, Cecilie E. Kiserud, Bård Mannsåker, Oluf Dimitri Røe, Alina Carmen Porojnicu, Gry Aarum Geitvik, Helle Kristine Skjerven, H.E.G. Russnes, Elin Borgen, Pernilla Turunen Olsson, Bjørnar Gilje, Jon Lømo, Lars A. Akslen, Sunil Xavier Raj, Torgunn Kursetgjerde, Lars Asphaug, Hege Oma Ohnstad, Berit Gravdehaug, Beate Boge, Silje Songe-Møller, Magdalena A Vestlid, Egil Støre Blix, Anita Langerød, Anette Heie, Elin Mortensen, Emiel A. M. Janssen, Mette Brekke
article en
2 citations

Abstract

Using the Prosigna-assay for all HR+/HER2- pN0 EBC patients was not cost-effective from a healthcare perspective, but from the societal perspective it was cost-saving. Selecting patients who are clear/uncertain candidates for chemotherapy based on IHC-classification, Prosigna is cost-effective from both perspectives.

Clinical Breast CancerVol. 25(6)
Oslo University Hospital (NO), University Hospital of North Norway (NO), University of Oslo (NO), Innlandet Hospital Trust (NO), Stavanger University Hospital (NO), Akershus University Hospital (NO), Levanger Hospital (NO), Vestre Viken Hospital Trust (NO), Haukeland University Hospital (NO), Hospital of Southern Norway (NO), Ålesund Hospital (NO), St Olav's University Hospital (NO), Nordland Hospital (NO), Telemark Hospital (NO), Østfold Hospital Trust (NO), UiT The Arctic University of Norway (NO)
Openalex Percentile: Top 15%
Breast Cancer Treatment Studies
1.87
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.